{"id":"dopamine-agonists","safety":{"commonSideEffects":[{"rate":"20-40","effect":"Nausea"},{"rate":"15-30","effect":"Dizziness"},{"rate":"10-25","effect":"Orthostatic hypotension"},{"rate":"5-15","effect":"Hallucinations"},{"rate":"10-20","effect":"Somnolence"},{"rate":"5-10","effect":"Impulse control disorders"},{"rate":"10-15","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Dopamine agonists are a class of drugs that directly stimulate dopamine receptors (D1, D2, D3, D4, or D5 subtypes) or increase dopamine availability in the central nervous system. By activating these receptors, they restore dopaminergic signaling in conditions where dopamine levels or receptor function are impaired, such as Parkinson's disease or hyperprolactinemia.","oneSentence":"Dopamine agonists bind to and activate dopamine receptors in the brain, mimicking the effects of the neurotransmitter dopamine.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:44:55.724Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Parkinson's disease"},{"name":"Restless legs syndrome"},{"name":"Hyperprolactinemia"},{"name":"Pituitary adenoma (prolactin-secreting)"}]},"trialDetails":[{"nctId":"NCT07492160","phase":"PHASE2","title":"Efficacy of Cabergoline in Inhibiting Lactation and Alleviating Breast Symptoms","status":"RECRUITING","sponsor":"Maimonides Medical Center","startDate":"2026-03-16","conditions":"Pregnancy, Abortion","enrollment":348},{"nctId":"NCT03947216","phase":"PHASE2","title":"Randomized Placebo Controlled Trial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5-HydroxyTryptamine-2A (5HT2A) Inverse Agonist, to Treat Impulse Control Disorders in Parkinson's Disease.","status":"COMPLETED","sponsor":"University Hospital, Strasbourg, France","startDate":"2020-10-23","conditions":"Parkinson Disease","enrollment":117},{"nctId":"NCT07151378","phase":"PHASE3","title":"Intestinal Levodopa + Entacapone Therapy (Lecigon®) to Counteract Dopaminergic Desensitization and Neuropsychiatric Complications in Parkinson's Disease","status":"RECRUITING","sponsor":"University Hospital Tuebingen","startDate":"2025-10-27","conditions":"PARKINSON DISEASE (Disorder)","enrollment":150},{"nctId":"NCT06295952","phase":"PHASE2","title":"A Study of Pasireotide in People With Prolactinoma","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2024-02-27","conditions":"Prolactin-Producing Pituitary Tumor","enrollment":10},{"nctId":"NCT07386080","phase":"PHASE4","title":"Carbergoline for Antipsychotic Induced Hyperprolactinemia.","status":"NOT_YET_RECRUITING","sponsor":"Zealand University Hospital","startDate":"2026-05-01","conditions":"Scizophrenia","enrollment":146},{"nctId":"NCT07313176","phase":"","title":"Long Term Effectiveness of Levodopa-Entacapone-Carbidopa Intestinal Gel in Participants With Advanced Parkinson's Disease","status":"RECRUITING","sponsor":"Britannia Pharmaceuticals Ltd.","startDate":"2026-01","conditions":"Advanced Parkinson Disease","enrollment":215},{"nctId":"NCT05043103","phase":"","title":"Long-Term Observational Study on Effectiveness and Safety of Lecigon in Patients With Advanced Parkinson's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Britannia Pharmaceuticals Ltd.","startDate":"2021-07-06","conditions":"Advanced Parkinson Disease","enrollment":312},{"nctId":"NCT02220309","phase":"","title":"Stanford RAD-AT Study (Research on Anxiety and Depression - Anhedonia Treatment)","status":"COMPLETED","sponsor":"Stanford University","startDate":"2013-08-11","conditions":"Anxiety, Depression","enrollment":167},{"nctId":"NCT06052787","phase":"PHASE3","title":"Combined Cerebrolysin and Amantadine Sulfate Administration for Patients With Traumatic Brain Injury in the ICU","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2023-09-01","conditions":"Traumatic Brain Injury","enrollment":150},{"nctId":"NCT07072910","phase":"PHASE2","title":"Cabergoline for Episodic Migraine","status":"RECRUITING","sponsor":"Aarhus University Hospital","startDate":"2025-11-12","conditions":"Migraine","enrollment":150},{"nctId":"NCT06029673","phase":"PHASE2","title":"Cabergoline for Lactation Inhibition After Early Second-Trimester Abortion or Pregnancy Loss","status":"COMPLETED","sponsor":"Stanford University","startDate":"2024-02-07","conditions":"Lactation Suppressed","enrollment":69},{"nctId":"NCT07045935","phase":"PHASE4","title":"Metabolic Outcomes in Patients With Prolactinomas Under Dopamine Agonist Treatment","status":"RECRUITING","sponsor":"University Hospital, Basel, Switzerland","startDate":"2025-09-16","conditions":"Prolactinoma","enrollment":60},{"nctId":"NCT06726785","phase":"","title":"Observe Change in Nasal Swab DRD2 Gene Expression in Restless Legs Syndrome (RLS) Patients on Prolonged Dopamine Agonist Treatment","status":"RECRUITING","sponsor":"HBC Immunology Inc","startDate":"2025-07-01","conditions":"Restless Leg Syndrome (RLS)","enrollment":50},{"nctId":"NCT02339064","phase":"PHASE3","title":"Infusion of Apomorphine: Long-term Safety Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals","startDate":"2015-02","conditions":"Idiopathic Parkinson's Disease","enrollment":99},{"nctId":"NCT02288962","phase":"PHASE3","title":"Dopamine Agonist Treatment of Non-functioning Pituitary Adenomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Olavs Hospital","startDate":"2014-11","conditions":"Pituitary Neoplasms, Adenoma","enrollment":60},{"nctId":"NCT04887467","phase":"PHASE4","title":"Monocentric, Prospective Study to Assess the Pharmacokinetic Profile of Continuous and Diurnal Subcutaneous Apomorphine Infusion in Patients With Parkinson's Disease","status":"COMPLETED","sponsor":"Rennes University Hospital","startDate":"2021-09-16","conditions":"Parkinson Disease","enrollment":19},{"nctId":"NCT00465452","phase":"PHASE3","title":"Impact of Switching to Continuous Release Dopamine Agonists","status":"COMPLETED","sponsor":"University of Toledo","startDate":"2007-01","conditions":"Parkinson Disease","enrollment":11},{"nctId":"NCT03911726","phase":"NA","title":"Do Antipsychotic Agents Induce Supersensitivity in Humans: A Combined PET/MRI Study in Patients With Schizophrenia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Central Institute of Mental Health, Mannheim","startDate":"2020-08-01","conditions":"Schizophrenia","enrollment":140},{"nctId":"NCT06754553","phase":"","title":"Trial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5-HydroxyTryptamine-2A (5HT2A) Inverse Agonist, to Treat Impulse Control Disorders in Parkinson's Disease.","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Strasbourg, France","startDate":"2025-02","conditions":"Parkinson Disease","enrollment":100},{"nctId":"NCT05585827","phase":"NA","title":"Online Cognitive Behavioral Therapy for Depressive Symptoms in Parkinson's Disease","status":"COMPLETED","sponsor":"Helse Stavanger HF","startDate":"2022-12-07","conditions":"Parkinson Disease, Depressive Symptoms, Anxiety","enrollment":11},{"nctId":"NCT05001217","phase":"PHASE2, PHASE3","title":"Chinese Herbal Medicine Treatment as Adjunct Therapy for Parkinson's Disease","status":"COMPLETED","sponsor":"Hong Kong Baptist University","startDate":"2022-01-01","conditions":"Parkinson Disease","enrollment":160},{"nctId":"NCT04332276","phase":"PHASE1, PHASE2","title":"Dopaminergic RestauratIon by IntraVEntriculaire Administration","status":"COMPLETED","sponsor":"University Hospital, Lille","startDate":"2020-09-18","conditions":"Parkinson Disease","enrollment":12},{"nctId":"NCT06612593","phase":"PHASE2","title":"Cilostazol in Parkinson's Disease","status":"NOT_YET_RECRUITING","sponsor":"Ain Shams University","startDate":"2024-10-01","conditions":"Parkinson's Disease","enrollment":50},{"nctId":"NCT06468371","phase":"NA","title":"Exercise Training Versus Ropinirole in Treating Restless Legs Syndrome Among Hemodialysis Patients","status":"COMPLETED","sponsor":"Lahore General Hospital","startDate":"2022-01-02","conditions":"Hemodialysis, Restless Legs Syndrome, ESRD (End Stage Renal Disease)","enrollment":84},{"nctId":"NCT03038308","phase":"PHASE1, PHASE2","title":"Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole","status":"COMPLETED","sponsor":"Columbia University","startDate":"2016-09-16","conditions":"Hyperprolactinemia, Prolactinoma","enrollment":16},{"nctId":"NCT06365190","phase":"NA","title":"Effects of a Periodic Repetitive Transcranial Magenetic Stimulation in Parkinson Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Anhui Medical University","startDate":"2020-04-06","conditions":"Transcranial Magnetic Stimulation, Parkinson's Disease","enrollment":47},{"nctId":"NCT04701333","phase":"PHASE2","title":"Cabergoline for Lactation Inhibition After Second-Trimester Abortion or Loss","status":"COMPLETED","sponsor":"Stanford University","startDate":"2021-04-01","conditions":"Lactation Suppressed","enrollment":73},{"nctId":"NCT05610189","phase":"PHASE1","title":"Multiple-dose Trial to Determine the Clinical Bioequivalence Between Tavapadon Tablets in Participants With Parkinson's Disease","status":"COMPLETED","sponsor":"Cerevel Therapeutics, LLC","startDate":"2022-12-15","conditions":"Parkinson Disease","enrollment":25},{"nctId":"NCT03738618","phase":"PHASE3","title":"Recombinant FSH Investigation in the Treatment of Infertility With Assisted Reproductive Technology (ART) (RITA-2)","status":"COMPLETED","sponsor":"Ferring Pharmaceuticals","startDate":"2018-10-29","conditions":"Infertility, Female","enrollment":588},{"nctId":"NCT03740737","phase":"PHASE3","title":"Recombinant FSH Investigation in the Treatment of Infertility With Assisted Reproductive Technology (ART) (RITA-1)","status":"COMPLETED","sponsor":"Ferring Pharmaceuticals","startDate":"2018-10-26","conditions":"Infertility","enrollment":579},{"nctId":"NCT03000569","phase":"PHASE2","title":"A Study to Evaluate SAGE-217 in Participants With Parkinson's Disease","status":"COMPLETED","sponsor":"Biogen","startDate":"2016-11-30","conditions":"Parkinson Disease","enrollment":29},{"nctId":"NCT03693872","phase":"NA","title":"Evaluation of the Nonmotor Symptomatology of Parkinsonian Patients Treated With Two Strategies Related to Apomorphine Pump Therapy in French Hospitals","status":"COMPLETED","sponsor":"Rennes University Hospital","startDate":"2019-05-15","conditions":"Parkinson Disease","enrollment":43},{"nctId":"NCT03665493","phase":"NA","title":"Dopamine Effect on Inhibitory Control","status":"COMPLETED","sponsor":"Giovanni Mirabella","startDate":"2020-09-30","conditions":"Idiopathic Parkinson's Disease","enrollment":90},{"nctId":"NCT06110507","phase":"","title":"Chronic Anergic-anhedonic Depression Open Trial","status":"UNKNOWN","sponsor":"University Hospital, Strasbourg, France","startDate":"2023-04-01","conditions":"Depressive Disorder, Treatment-Resistant","enrollment":60},{"nctId":"NCT04249544","phase":"PHASE1","title":"Social Decision Making in Parkinson's Disease","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2019-12-03","conditions":"Parkinson Disease","enrollment":18},{"nctId":"NCT04674670","phase":"NA","title":"Psychobiological Mechanisms Underlying Chronic Pain","status":"COMPLETED","sponsor":"susanne becker","startDate":"2021-11-01","conditions":"Fibromyalgia, Pain, Chronic, Chronic Pain, Widespread","enrollment":48},{"nctId":"NCT02671240","phase":"","title":"Prognosis of Behavioral Addiction in Parkinson's Disease","status":"TERMINATED","sponsor":"University Hospital, Strasbourg, France","startDate":"2016-10-24","conditions":"Addiction","enrollment":164},{"nctId":"NCT01528462","phase":"","title":"Sleep Disorders Managed and Assessed Rapidly in Transient Ischemic Attack (TIA) and In Early Stroke","status":"COMPLETED","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2011-10","conditions":"Stroke, Ischemic Attack, Transient, Sleep Disorders","enrollment":97},{"nctId":"NCT01770145","phase":"PHASE4","title":"Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT)","status":"COMPLETED","sponsor":"MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals","startDate":"2012-12","conditions":"Parkinson's Disease, Motor Symptoms, Akinesia","enrollment":127},{"nctId":"NCT04262024","phase":"PHASE1","title":"Clinical Guidance for Proper Treatment of Unexplained Resistant Hyperprolactinemia.","status":"COMPLETED","sponsor":"Woman's Health University Hospital, Egypt","startDate":"2020-02-01","conditions":"Health Education","enrollment":120},{"nctId":"NCT03250117","phase":"PHASE1, PHASE2","title":"Relative Bioavailability Study of Ropinirole Implants in Parkinson's Patients on L-Dopa Switched From Oral Ropinirole","status":"TERMINATED","sponsor":"Titan Pharmaceuticals","startDate":"2017-10-10","conditions":"Parkinson Disease","enrollment":6},{"nctId":"NCT02579473","phase":"PHASE1","title":"A Study of Weekly Subcutaneous Injections of SER-214 in Subjects With Parkinson's Disease (PD), to Determine the Safety, Tolerability and Pharmacokinetic (PK) Profile of SER-214","status":"UNKNOWN","sponsor":"Serina Therapeutics","startDate":"2016-01","conditions":"Parkinson's Disease","enrollment":20},{"nctId":"NCT05640986","phase":"NA","title":"Use of BART Coupled With EEG in the Early Diagnosis of Behavioral Disorders in Parkinson's Disease","status":"NOT_YET_RECRUITING","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"2023-01-02","conditions":"Parkinson Disease","enrollment":80},{"nctId":"NCT05405244","phase":"PHASE3","title":"Examination of Bromocriptine on Homeostatic and Hedonic Mechanisms of Food Intake in Individuals at High Risk for T2DM","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2017-09-19","conditions":"Overweight and Obesity, Eating Behavior","enrollment":55},{"nctId":"NCT03708237","phase":"PHASE2","title":"Effectiveness of Ropinirole and Gabapentin for the Treatment of RLS in Patients on Maintenance HD","status":"TERMINATED","sponsor":"University of Alberta","startDate":"2019-02-19","conditions":"Restless Legs Syndrome, End Stage Renal Disease","enrollment":3},{"nctId":"NCT03158090","phase":"","title":"The Longitudinal Approach to Acromegaly: A Pattern of Treatment and Comparative Effectiveness Research","status":"RECRUITING","sponsor":"Ginkgo Leaf Center for Rare Disorders","startDate":"2017-12-15","conditions":"Acromegaly","enrollment":1965},{"nctId":"NCT03817554","phase":"PHASE4","title":"Pramipexole for Restless Leg Syndrome in Peritoneal Dialysis Patients","status":"TERMINATED","sponsor":"Dong Jie","startDate":"2019-07-01","conditions":"Restless Legs Syndrome","enrollment":21},{"nctId":"NCT02929485","phase":"PHASE4","title":"Dopaminergic Modulation of Frontostriatal Function With a Dopamine Agonist and COMT Inhibitor","status":"WITHDRAWN","sponsor":"University of California, Berkeley","startDate":"2013-07","conditions":"Addiction","enrollment":""},{"nctId":"NCT02896816","phase":"NA","title":"EMG Modules as a Novel Biomarker of Basal Ganglia Plasticity in Parkinson's Disease","status":"TERMINATED","sponsor":"Spaulding Rehabilitation Hospital","startDate":"2016-08","conditions":"Parkinson","enrollment":17},{"nctId":"NCT05044520","phase":"","title":"Clinical Features Associated With Restless Legs Syndrome.","status":"RECRUITING","sponsor":"University Hospital, Montpellier","startDate":"2021-09-01","conditions":"Restless Legs Syndrome","enrollment":2000},{"nctId":"NCT01683253","phase":"PHASE4","title":"Remission of ICD by Switching Dopamine Agonist to Levodopa/Carbidopa","status":"COMPLETED","sponsor":"Sandoz","startDate":"2012-11","conditions":"Impulse Control Disorder","enrollment":150},{"nctId":"NCT00537017","phase":"PHASE2","title":"Follow Up Safety Study of SCH 420814 in Subjects With Parkinson's Disease (P05175)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-11-23","conditions":"Parkinson Disease, Neurodegenerative Diseases, Central Nervous System Diseases","enrollment":140},{"nctId":"NCT04107480","phase":"PHASE4","title":"PRolaCT - Three Prolactinoma RCTs","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2019-06-21","conditions":"Prolactinoma, Prolactin-Producing Pituitary Tumor","enrollment":880},{"nctId":"NCT02365870","phase":"PHASE4","title":"Anxiety in Parkinson's: Use of Quantitative Methods to Guide Rational Treatment","status":"TERMINATED","sponsor":"Johns Hopkins University","startDate":"2016-08","conditions":"Anxiety Disorders, Parkinson Disease","enrollment":4},{"nctId":"NCT03681509","phase":"NA","title":"Pramipexole and Emotional Processing","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2018-09-01","conditions":"Emotions, Motivation, Reward","enrollment":43},{"nctId":"NCT02542410","phase":"PHASE2","title":"Dopamine Receptor Agonist Therapy for Pain Relief in Women Suffering From Endometriosis: A Pilot Study","status":"COMPLETED","sponsor":"Boston Children's Hospital","startDate":"2016-05","conditions":"Endometriosis","enrollment":10},{"nctId":"NCT03918616","phase":"","title":"P2X7 Receptor, Inflammation and Neurodegenerative Diseases","status":"COMPLETED","sponsor":"University of Pisa","startDate":"2017-02-20","conditions":"Neuro-Degenerative Disease","enrollment":50},{"nctId":"NCT03665454","phase":"PHASE1","title":"PF 06412562 in Subjects With Advanced Stage Parkinson's Disease","status":"COMPLETED","sponsor":"Milton S. Hershey Medical Center","startDate":"2018-09-24","conditions":"Parkinson Disease","enrollment":8},{"nctId":"NCT00360633","phase":"","title":"Psychiatric and Cognitive Manifestations of Parkinson's Disease","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2006-06","conditions":"Parkinson's Disease","enrollment":36},{"nctId":"NCT02812147","phase":"PHASE2","title":"Effect of L-Dihydoxyphenylserine on Locomotion, Postural Stability, and Fall Risk Reduction in Parkinson Disease","status":"UNKNOWN","sponsor":"St. Joseph's Hospital and Medical Center, Phoenix","startDate":"2016-05","conditions":"Parkinson Disease","enrollment":20},{"nctId":"NCT03717454","phase":"NA","title":"Dopamine D2 Receptors(D2R) Imaging in Prolactinomas","status":"UNKNOWN","sponsor":"Zhebao Wu","startDate":"2018-12-01","conditions":"Prolactinoma","enrollment":50},{"nctId":"NCT00406029","phase":"PHASE2","title":"Dyskinesia in Parkinson's Disease (Study P04501)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-11-20","conditions":"Parkinson Disease, Movement Disorders, Central Nervous System Diseases","enrollment":253},{"nctId":"NCT03714763","phase":"NA","title":"Dopamine D2 Receptors(D2R) Imaging in Nonfunctioning Pituitary Adenoma(NFPA)","status":"UNKNOWN","sponsor":"Zhebao Wu","startDate":"2018-11-01","conditions":"Pituitary Adenoma","enrollment":50},{"nctId":"NCT00599339","phase":"","title":"Transdermal Rotigotine User Surveillance Study","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2006-06","conditions":"Idiopathic Parkinson Disease","enrollment":2195},{"nctId":"NCT03218969","phase":"PHASE1, PHASE2","title":"Treatment of Restless Leg Syndrome (RLS) Augmentation With Ecopipam, a D1 Specific Antagonist","status":"UNKNOWN","sponsor":"William Ondo, MD","startDate":"2017-09-18","conditions":"Restless Legs Syndrome, Augmentation","enrollment":10},{"nctId":"NCT01823770","phase":"PHASE4","title":"Effect of Rotigotine Patch Treatment on Cardiovascular Markers in Idiopathic Restless Legs Syndrome","status":"COMPLETED","sponsor":"University Hospital, Montpellier","startDate":"2012-11-26","conditions":"Restless Legs Syndrome (RLS)","enrollment":130},{"nctId":"NCT02507206","phase":"PHASE2","title":"A D1 Agonist For Working Memory","status":"COMPLETED","sponsor":"Antonia New","startDate":"2013-04","conditions":"Schizotypal Personality Disorder, SPD","enrollment":120},{"nctId":"NCT01733199","phase":"PHASE4","title":"Behavioural Addictions Occurring During a Dopaminergic Treatment Prescribe Under Parkinson's Disease: Study of the Psychopathological, Neurological, Pharmacokinetic and Genetic Profiles","status":"COMPLETED","sponsor":"Nantes University Hospital","startDate":"2012-10","conditions":"Parkinson's Disease, Secondary Behavioural Addiction","enrollment":225},{"nctId":"NCT03353025","phase":"NA","title":"Study on Therapy of Non-invasive Prolactinoma","status":"UNKNOWN","sponsor":"First Affiliated Hospital, Sun Yat-Sen University","startDate":"2016-01-01","conditions":"Prolactinoma","enrollment":394},{"nctId":"NCT03336307","phase":"","title":"Predictors of Gait Improvement in Patients With Parkinson's Disease After Rehabilitation","status":"COMPLETED","sponsor":"University of Roma La Sapienza","startDate":"2014-05","conditions":"Parkinson Disease, Movement Disorders","enrollment":36},{"nctId":"NCT02786667","phase":"PHASE3","title":"Non Motors Aspects in De Novo Parkinson's Disease","status":"UNKNOWN","sponsor":"University Hospital, Grenoble","startDate":"2012-06","conditions":"Parkinson Disease, Apathy","enrollment":199},{"nctId":"NCT03271918","phase":"PHASE3","title":"Cabergoline in Nonfunctioning Pituitary Adenomas","status":"COMPLETED","sponsor":"University of Sao Paulo General Hospital","startDate":"2015-02-01","conditions":"Pituitary Adenoma, Nonfunctioning Pituitary Adenoma","enrollment":140},{"nctId":"NCT00051961","phase":"","title":"Effect of Ropinirole on Spinal Cord Reflexes and Restless Legs Syndrome","status":"COMPLETED","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"2003-01-14","conditions":"Restless Legs Syndrome","enrollment":90},{"nctId":"NCT02536261","phase":"","title":"Dopamine Agonists Withdrawal Study of Invasive Prolactinomas Involving the Cavernous Sinus","status":"UNKNOWN","sponsor":"Zhebao Wu","startDate":"2016-06","conditions":"Invasive Prolactinomas Involving the Cavernous Sinus","enrollment":30},{"nctId":"NCT03151460","phase":"PHASE4","title":"Dopaminergic Modulation of Declarative Memory","status":"COMPLETED","sponsor":"I.R.C.C.S. Fondazione Santa Lucia","startDate":"2014-09","conditions":"Parkinson's Disease","enrollment":40},{"nctId":"NCT01338662","phase":"","title":"Comparison of the Incidence of Dyskinesia in Parkinson's Disease Who Were Treated With Amantadine or Dopamine Agonist","status":"UNKNOWN","sponsor":"Seoul National University Hospital","startDate":"2011-05","conditions":"Parkinson's Disease","enrollment":500},{"nctId":"NCT01278342","phase":"PHASE4","title":"Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-09","conditions":"Acromegaly","enrollment":70},{"nctId":"NCT02319395","phase":"","title":"Behavioural Addiction and Genetics in Parkinson's Disease","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2011-11","conditions":"Parkinson Disease, Impulse Control Disorders","enrollment":332},{"nctId":"NCT01976871","phase":"PHASE4","title":"Switching From Oral Dopamine Agonists to Rotigotine","status":"COMPLETED","sponsor":"John Winkelman, MD, PhD","startDate":"2014-08","conditions":"Restless Legs Syndrome, Ekbom Syndrome, Willis-Ekbom Disease","enrollment":21},{"nctId":"NCT02969629","phase":"PHASE4","title":"The Effects of Apomorphine on Experimental and Clinical Pain in Patients With Chronic Radicular Pain","status":"COMPLETED","sponsor":"Rambam Health Care Campus","startDate":"2012-12","conditions":"Chronic Low Back Pain","enrollment":59},{"nctId":"NCT01744964","phase":"EARLY_PHASE1","title":"Apomorphine Effects on Experimental Pain","status":"COMPLETED","sponsor":"Rambam Health Care Campus","startDate":"2009-07","conditions":"Healthy","enrollment":105},{"nctId":"NCT01620138","phase":"PHASE2, PHASE3","title":"Response to Cabergoline and Pasireotide in Non-functioning Pituitary Adenomas and Resistant Prolactinomas","status":"COMPLETED","sponsor":"Universidade Federal do Rio de Janeiro","startDate":"2010-03","conditions":"Non-functioning Pituitary Adenomas, Prolactinomas","enrollment":21},{"nctId":"NCT01049984","phase":"PHASE4","title":"Rasagiline as Add on to Dopamine Agonists in the Treatment of Parkinson's Disease","status":"COMPLETED","sponsor":"Teva Neuroscience, Inc.","startDate":"2009-12","conditions":"Parkinson's Disease","enrollment":328},{"nctId":"NCT01052831","phase":"PHASE4","title":"Naltrexone for Impulse Control Disorders in Parkinson's Disease","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2009-11","conditions":"Impulse Control Disorder, Parkinson Disease","enrollment":50},{"nctId":"NCT00334048","phase":"PHASE4","title":"Treating Sexual Dysfunction From Selective Serotonin Reuptake Inhibitor (SSRI) Medication: a Study Comparing Requip CR to Placebo","status":"COMPLETED","sponsor":"St. Luke's-Roosevelt Hospital Center","startDate":"2006-06","conditions":"Sexual Dysfunction","enrollment":9},{"nctId":"NCT02347059","phase":"PHASE2","title":"L-dopa Versus Dopamine Agonists After Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease","status":"UNKNOWN","sponsor":"University of Toronto","startDate":"2015-01","conditions":"Parkinson's Disease","enrollment":40},{"nctId":"NCT00443872","phase":"PHASE4","title":"Efficacy of Orally Disintegrating Selegiline in Parkinson's Patients Experiencing Adverse Effects With Dopamine Agonists","status":"COMPLETED","sponsor":"Parkinson's Disease and Movement Disorder Center of Boca Raton","startDate":"2007-03","conditions":"Parkinson's Disease","enrollment":77},{"nctId":"NCT00522379","phase":"PHASE3","title":"Trial to Assess Parkinson's Disease (PD) Symptom Control to Four Doses of Rotigotine in a Transdermal Patch","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2007-07","conditions":"Parkinson's Disease","enrollment":514},{"nctId":"NCT02116790","phase":"PHASE2","title":"Efficacy of Co-administration of an NSAID With a Dopamine Agonist In Healthy Subjects","status":"WITHDRAWN","sponsor":"Northwestern University","startDate":"2014-05","conditions":"Acute Pain","enrollment":""},{"nctId":"NCT02236741","phase":"","title":"The Use of Pramipexole and Other Dopamine Agonists and the Risks of Heart Failure and Pneumonia","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2009-11","conditions":"Heart Failure","enrollment":26814},{"nctId":"NCT02233023","phase":"PHASE4","title":"Ophthalmologic Safety of Long Term Treatment With Pramipexole Compared to Bromocriptine or Other Dopamine Agonists in Patients With Parkinson's Disease","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"1998-06","conditions":"Parkinson Disease","enrollment":705},{"nctId":"NCT02231905","phase":"PHASE4","title":"Safety, Tolerability and Efficacy of Switching From Talipexole to Pramipexole in Patients With Parkinson's Disease","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2004-01","conditions":"Parkinson Disease","enrollment":29},{"nctId":"NCT00297778","phase":"PHASE4","title":"Pramipexole Versus Placebo in Parkinson's Disease (PD) Patients With Depressive Symptoms","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2006-03","conditions":"Parkinson Disease, Depression","enrollment":296},{"nctId":"NCT01711866","phase":"PHASE4","title":"A Phase 4, Open-label Study to Assess the Feasibility and Efficacy on Motor and Non-motor Symptoms of Switching From Pramipexole or Ropinirole to Rotigotine Transdermal Patch in Subjects With Advanced Idiopathic Parkinson's Disease","status":"COMPLETED","sponsor":"UCB BIOSCIENCES GmbH","startDate":"2012-09","conditions":"Advanced Idiopathic Parkinson's Disease","enrollment":87},{"nctId":"NCT02100176","phase":"","title":"MIRT and Rotigotine in the Early Stage of PD","status":"UNKNOWN","sponsor":"Ospedale Generale Di Zona Moriggia-Pelascini","startDate":"2013-01","conditions":"Parkinson's Disease","enrollment":40},{"nctId":"NCT00144209","phase":"PHASE3","title":"Assess Efficacy and Safety of the Dopamine Agonist Pramipexole Versus Levodopa / Benserazide (Madopar® DR) in Patients With Restless Legs Syndrome","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2003-02","conditions":"Restless Legs Syndrome","enrollment":58},{"nctId":"NCT00605683","phase":"PHASE3","title":"MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist","status":"COMPLETED","sponsor":"Newron Pharmaceuticals SPA","startDate":"2007-11","conditions":"Idiopathic Parkinson's Disease","enrollment":679},{"nctId":"NCT01106053","phase":"PHASE3","title":"Pramipexole for Binge Eating Disorder","status":"WITHDRAWN","sponsor":"Neuropsychiatric Research Institute, Fargo, North Dakota","startDate":"2010-04","conditions":"Binge Eating Disorder","enrollment":""},{"nctId":"NCT01028586","phase":"PHASE3","title":"MOTION, Safinamide in Early Idiopathic Parkinson's Disease (IPD), as add-on to Dopamine Agonist (Extension of Trial 27918)","status":"TERMINATED","sponsor":"Newron Pharmaceuticals SPA","startDate":"2009-10","conditions":"Idiopathic Parkinson's Disease","enrollment":507},{"nctId":"NCT00627640","phase":"PHASE3","title":"Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa","status":"COMPLETED","sponsor":"Newron Pharmaceuticals SPA","startDate":"2009-02","conditions":"Idiopathic Parkinson's Disease","enrollment":549}],"_emaApprovals":[],"_faersSignals":[{"count":2,"reaction":"HALLUCINATION"},{"count":1,"reaction":"AGITATION"},{"count":1,"reaction":"ANXIETY"},{"count":1,"reaction":"BALANCE DISORDER"},{"count":1,"reaction":"BRADYPHRENIA"},{"count":1,"reaction":"CHOLECYSTITIS"},{"count":1,"reaction":"COGNITIVE DISORDER"},{"count":1,"reaction":"CONFUSIONAL STATE"},{"count":1,"reaction":"CONSTIPATION"},{"count":1,"reaction":"COVID-19"}],"_approvalHistory":[],"publicationCount":5188,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Standard Care"],"phase":"marketed","status":"active","brandName":"Dopamine Agonists","genericName":"Dopamine Agonists","companyName":"Leiden University Medical Center","companyId":"leiden-university-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Dopamine agonists bind to and activate dopamine receptors in the brain, mimicking the effects of the neurotransmitter dopamine. Used for Parkinson's disease, Restless legs syndrome, Hyperprolactinemia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":15,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}